Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
7.98
-0.10 (-1.24%)
Aug 7, 2026, 9:30 AM EDT - Market open
Akari Therapeutics, Employees
As of December 31, 2025, Akari Therapeutics, had 6 total employees, including 5 full-time and 1 part-time employees. The number of employees decreased by 3 or -33.33% compared to the previous year.
Employees
6
Change (1Y)
-3
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$4,674,667
Market Cap
13.97M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 6 | -3 | -33.33% | 5 | 1 |
| Dec 31, 2024 | 9 | -3 | -25.00% | 8 | 1 |
| Dec 31, 2023 | 12 | -3 | -20.00% | 9 | 3 |
| Dec 31, 2022 | 15 | 6 | 66.67% | 15 | 0 |
| Dec 31, 2021 | 9 | 0 | - | 9 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Palatin Technologies | 29 |
| BioLineRx | 24 |
| Passage Bio | 24 |
| SeaStar Medical Holding | 17 |
| CalciMedica | 16 |
| BioVie | 13 |
| Cocrystal Pharma | 10 |
| KALA BIO | 6 |
AKTX News
- 3 days ago - Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation - GlobeNewsWire
- 16 days ago - Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity - GlobeNewsWire
- 17 days ago - Akari Therapeutics enters research collaboration with Whitehawk Therapeutics - TheFly
- 17 days ago - Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics - GlobeNewsWire
- 18 days ago - Maxim upgrades Akari Therapeutics to Buy on AKTX-101 data, ADC M&A - TheFly
- 18 days ago - Akari Therapeutics upgraded to Buy from Hold at Maxim - TheFly
- 4 weeks ago - Akari Therapeutics, Registration statement: Registration filing - Filings
- 4 weeks ago - Akari Therapeutics, Registration statement: Registration filing - Filings